These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

649 related articles for article (PubMed ID: 31150120)

  • 81. Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the
    Kong A; Good J; Kirkham A; Savage J; Mant R; Llewellyn L; Parish J; Spruce R; Forster M; Schipani S; Harrington K; Sacco J; Murray P; Middleton G; Yap C; Mehanna H
    BMJ Open; 2020 Mar; 10(3):e033009. PubMed ID: 32184305
    [TBL] [Abstract][Full Text] [Related]  

  • 82. A phase II randomized trial comparing neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in advanced squamous cell carcinoma of the pharynx or larynx.
    Huang PW; Lin CY; Hsieh CH; Hsu CL; Fan KH; Huang SF; Liao CT; Ng SK; Yen TC; Chang JT; Wang HM
    Biomed J; 2018 Apr; 41(2):129-136. PubMed ID: 29866601
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study.
    Powell SF; Gold KA; Gitau MM; Sumey CJ; Lohr MM; McGraw SC; Nowak RK; Jensen AW; Blanchard MJ; Fischer CD; Bykowski J; Ellison CA; Black LJ; Thompson PA; Callejas-Valera JL; Lee JH; Cohen EEW; Spanos WC
    J Clin Oncol; 2020 Jul; 38(21):2427-2437. PubMed ID: 32479189
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Phase II trial of concurrent bio-chemoradiotherapy using docetaxel, cisplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma.
    Nishimura G; Taguchi T; Takahashi M; Shiono O; Komatsu M; Sano D; Yabuki K; Arai Y; Takahashi H; Hata M; Oridate N
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1315-9. PubMed ID: 27154176
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Prognostic Value of Radiological Extranodal Extension Detected by Computed Tomography for Predicting Outcomes in Patients With Locally Advanced Head and Neck Squamous Cell Cancer Treated With Radical Concurrent Chemoradiotherapy.
    Mahajan A; Chand A; Agarwal U; Patil V; Vaish R; Noronha V; Joshi A; Kapoor A; Sable N; Ahuja A; Shukla S; Menon N; Agarwal JP; Laskar SG; D' Cruz A; Chaturvedi P; Chaukar D; Pai PS; Pantvaidya G; Thiagarajan S; Rane S; Prabhash K
    Front Oncol; 2022; 12():814895. PubMed ID: 35719994
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Prospective Study of Cetuximab, Carboplatin, and Radiation Therapy for Patients With Locally Advanced Head and Neck Squamous Cell Cancer Unfit for Cisplatin.
    Corry J; Bressel M; Fua T; Herschtal A; Solomon B; Porceddu SV; Wratten C; Rischin D
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):948-954. PubMed ID: 28483336
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Neoadjuvant Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation Versus Chemoradiation for Locally Advanced Cervical Cancer: A Randomized Phase II Trial.
    da Costa SCS; Bonadio RC; Gabrielli FCG; Aranha AS; Dias Genta MLN; Miranda VC; de Freitas D; Abdo Filho E; Ferreira PAO; Machado KK; Scaranti M; Carvalho HA; Estevez-Diz MDP
    J Clin Oncol; 2019 Nov; 37(33):3124-3131. PubMed ID: 31449470
    [TBL] [Abstract][Full Text] [Related]  

  • 88. c-Met expression is a marker of poor prognosis in patients with locally advanced head and neck squamous cell carcinoma treated with chemoradiation.
    Baschnagel AM; Williams L; Hanna A; Chen PY; Krauss DJ; Pruetz BL; Akervall J; Wilson GD
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):701-7. PubMed ID: 24521684
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III-IV unresectable head and neck cancer: Results of a randomized phase II study.
    Takácsi-Nagy Z; Hitre E; Remenár É; Oberna F; Polgár C; Major T; Gödény M; Fodor J; Kásler M
    Strahlenther Onkol; 2015 Aug; 191(8):635-41. PubMed ID: 25782685
    [TBL] [Abstract][Full Text] [Related]  

  • 90. A multicentric randomized controlled phase III trial of adaptive and 18F-FDG-PET-guided dose-redistribution in locally advanced head and neck squamous cell carcinoma (ARTFORCE).
    de Leeuw ALMP; Giralt J; Tao Y; Benavente S; France Nguyen TV; Hoebers FJP; Hoeben A; Terhaard CHJ; Wai Lee L; Friesland S; Steenbakkers RJHM; Tans L; Heukelom J; Kayembe MT; van Kranen SR; Bartelink H; Rasch CRN; Sonke JJ; Hamming-Vrieze O
    Radiother Oncol; 2024 Jul; 196():110281. PubMed ID: 38636708
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Weekly versus Three-Weekly Cisplatin-based Concurrent Chemoradiotherapy as definitive treatment in Head and Neck Cancer- Where do we stand?
    Rawat S; Srivastava H; Ahlawat P; Pal M; Gupta G; Chauhan D; Tandon S; Khurana R
    Gulf J Oncolog; 2016 May; 1(21):6-11. PubMed ID: 27250881
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Aspiration pneumonia in head and neck cancer patients undergoing concurrent chemoradiation from India: Findings from a post hoc analysis of a phase 3 study.
    Patil V; Noronha V; Shrirangwar S; Menon N; Abraham G; Chandrasekharan A; Prabhash K
    Cancer Med; 2021 Oct; 10(19):6725-6735. PubMed ID: 34498421
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
    Le Tourneau C; Tao Y; Gomez-Roca C; Cristina V; Borcoman E; Deutsch E; Bahleda R; Calugaru V; Modesto A; Rouits E; Gollmer K; Vuagniaux G; Crompton P; Zanna C; Szyldergemajn S; Delord JP; Bourhis J
    Clin Cancer Res; 2020 Dec; 26(24):6429-6436. PubMed ID: 32994295
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer.
    Beckham TH; Barney C; Healy E; Wolfe AR; Branstetter A; Yaney A; Riaz N; McBride SM; Tsai CJ; Kang J; Yu Y; Chen L; Sherman E; Dunn L; Pfister DG; Tan J; Rupert R; Bonomi M; Zhang Z; Lobaugh SM; Grecula JC; Mitchell DL; Wobb JL; Miller ED; Blakaj DM; Diavolitsis VM; Lee N; Bhatt AD
    Int J Cancer; 2020 Jul; 147(1):107-115. PubMed ID: 31609479
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis.
    Liu ZG; Zhao Y; Tang J; Zhou YJ; Yang WJ; Qiu YF; Wang H
    Oncotarget; 2016 Apr; 7(17):24429-35. PubMed ID: 27016412
    [TBL] [Abstract][Full Text] [Related]  

  • 96. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.
    Hitt R; Grau JJ; López-Pousa A; Berrocal A; García-Girón C; Irigoyen A; Sastre J; Martínez-Trufero J; Brandariz Castelo JA; Verger E; Cruz-Hernández JJ;
    Ann Oncol; 2014 Jan; 25(1):216-25. PubMed ID: 24256848
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
    Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
    Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Comparison of weekly administration of cisplatin versus three courses of cisplatin 100 mg/m(2) for definitive radiochemotherapy of locally advanced head-and-neck cancers.
    Rades D; Seidl D; Janssen S; Bajrovic A; Karner K; Strojan P; Schild SE
    BMC Cancer; 2016 Jul; 16():437. PubMed ID: 27391309
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer.
    Koutcher L; Sherman E; Fury M; Wolden S; Zhang Z; Mo Q; Stewart L; Schupak K; Gelblum D; Wong R; Kraus D; Shah J; Zelefsky M; Pfister D; Lee N
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):915-22. PubMed ID: 20947269
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck.
    Bauml JM; Vinnakota R; Anna Park YH; Bates SE; Fojo T; Aggarwal C; Limaye S; Damjanov N; Di Stefano J; Ciunci C; Genden EM; Wisnivesky JP; Ferrandino R; Mamtani R; Langer CJ; Cohen RB; Sigel K
    J Natl Cancer Inst; 2019 May; 111(5):490-497. PubMed ID: 30239887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.